Hopes Mount On Sun's 'Game Changer' Psoriasis Asset
Executive Summary
Sun Pharmaceutical Industries Ltd.'s late-stage psoriasis asset has met its primary endpoints in two pivotal studies, setting the stage for increased competition in a crowded and high stakes segment.
You may also be interested in...
Sun Underlines 'Competitive Profile' Of Psoriasis Asset In Crowded Market
India's Sun Pharma, the world's fifth largest specialty generic company, emphasized the "very competitive profile" of its late-stage psoriasis asset, tildrakizumab, at its Q2 earnings, but will that hold in a market that is expected to become increasingly saturated?
Sun Builds On Tildrakizumab Hopes With Almirall Pact
Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.